The Psilocybin Behavioral Health Access and Services Act sent by Senate President Nicholas Scutari to the Health, Human Services & Senior Citizens Committee several weeks ago, would legalize psilocybinâs production and use for mental health disorders such as depression, anxiety and end-of-life stress. Â
As Charles Toutant reports in the New Jersey Law Journal, the extended process to establish an infrastructure to produce & regulate cannabis has provided many opportunities for attorneys to participate.
Now, some people call the current legislation vague, with respect to the procedure for obtaining medical approval for the use of psilocybin as well as other points.Â
For instance, former Burlington County prosecutor Scott Coffina said New Jersey had âa very tight medical marijuana system,” while he is not sure whether he sees the same rigor in terms of demonstrating a need for the drug in the psychedelic mushrooms bill.Â
Coffina went on to explain his concerns over how the new legislation appears to be modeled on the medical marijuana law, yet the mechanism to qualify as a buyer and the role of the potential doctor supervising the treatment are unclear. He fears that the NJ psilocybin program could become like the early days after California legalized medical marijuana, with nearly anyone qualifying for a medical card.
When prosecutor Coffina said his office rarely summoned defendants for psilocybin possession, which like marijuana was usually viewed as a disorderly offense in municipal court. âMushrooms are far less concerning than cocaine or heroin,â he said.Â
On the other hand, the proposed act allows for home cultivation of psilocybin for individual use. On this point, Coffina manifested that growing mushrooms at home could lead to uncontrolled quality and potency while making it easier for children to access them.Â
The former prosecutor expressed his concern over legalized psilocybin potentially being the first step toward harder drugs. âAs someone who has been on the front lines of the opioid epidemic, Iâm hesitant over any law that sends a message to people, particularly young people, that itâs OK to put chemicals in your body to feel better, to change how youâre doing.â He added: âTo me, it inhibits independent coping skills, and once this amount of ingestion, whether itâs marijuana or mushrooms, isnât working, I think we could see an escalation to other drugs.â
Another bill commenter is co-chair of the cannabis industry practice group at Brach Eichler. Charles Gormally said that if the psilocybin bill passes, its market will be a fraction of the size of the cannabis market.Â
âIf you think about it, the cannabis opportunity attracted accountants and lawyers because essentially youâre taking a multi-billion dollar business that used to be a felony and turning it into a business in New Jersey. You donât have that size of market dealing with psychedelics or psilocybin products like mushrooms or LSD or anything like that. There is an interest in it,â Gormally explained.
He expressed opposition to the billâs call to create an advisory board. âThe one thing you donât need is more agencies that regulate a single, limited market. I think itâs not a prudent way to approach opportunities like this.â
The director of the Rebovich Institute for New Jersey Politics at Rider University in Lawrenceville, Micah Rasmussen, shared that while the measure towards legalizing recreational marijuana had wide public support, it is still unclear if the same will happen with magic mushrooms.Â
In his opinion, the mushroom bill would know better to learn from the consensus-building process and development of a regulatory framework of recreational cannabis before the psychedelic got to the market.
The approval of recreational cannabis was largely premised on social justice, which Rasmussen doesnât see in the present legislation proposal: âUnless Iâm missing something, that is not likely to be an argument with regard to who is using mushrooms or who is being arrested for them, and why they shouldnât be arrested.”
Be the first to comment